NEOGENOMICS INC — Form 8-K
Filed July 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
NeoGenomics reported Q2 2026 revenue of $202M (11% YoY growth) with clinical revenue up 14% and NGS revenue up 26%. The company raised full-year 2026 revenue guidance to $802–$806M (from $797–$803M) and adjusted EBITDA guidance to $56–$58M (from $55–$57M). Capital structure was strengthened by issuing $316M of 0.75% convertible notes due 2032, using proceeds to repurchase $276M of 0.25% convertible notes due 2028 and repurchase $25M in common stock. A $11M gain on debt extinguishment was recorded. The company also resolved a DOJ civil settlement regarding consulting services and submitted a third RaDaR ST reimbursement evidence submission to MolDx.
Why this rating
Modest revenue beat and guidance raise with strong NGS mix shift; debt refinancing at lower rate is favorable. However, adjusted EBITDA only $14M (2% of revenue) and Q2 GAAP net income only $2M—profitability remains constrained. Refinancing is constructive but not transformational. DOJ settlement behind it. Relative to $680M market cap, $4M raised in guidance midpoint is ~0.6% upside—meaningful but not dramatic for a $728M revenue company.
See more from July 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.